Ghrelin / GHSR-1a Signaling

Ghrelin is an acylated 28-amino-acid peptide hormone secreted predominantly from the gastric oxyntic mucosa that acts as the endogenous ligand for the growth hormone secretagogue receptor type 1a (GHSR-1a, also called GHS-R1a). The pathway controls pulsatile growth hormone (GH) release from pituitary somatotrophs, drives hypothalamic hunger circuits, modulates reward and mood via limbic GHSR-1a expression, and regulates glucose and lipid homeostasis at multiple peripheral sites. Several synthetic peptide and peptide-mimetic research compounds, including ipamorelin and hexarelin, act as selective GHSR-1a agonists; CJC-1295 engages the closely related GHRH receptor to synergize with this axis at the level of the somatotroph.

Pathway Components

The Ghrelin Peptide

Ghrelin is encoded by the GHRL gene (human chromosome 3p26-p25, UniProt Q9UBS5) as a 117-amino-acid prepropeptide. Proteolytic processing removes the signal peptide and the C-terminal obestatin-containing domain, yielding a 28-amino-acid mature ghrelin. A critical post-translational modification distinguishes active from inactive ghrelin: ghrelin O-acyltransferase (GOAT, MBOAT4, UniProt A0JLT2) attaches a medium-chain fatty acid, predominantly n-octanoic acid (C8:0), to the hydroxyl group of serine 3. This O-n-octanoylation is required for binding and activation of GHSR-1a; des-acyl ghrelin circulates in larger amounts but does not activate GHSR-1a and exerts separate effects through uncharacterized receptors. (PMID 10604470)

The primary source of circulating acyl-ghrelin is the X/A-like enteroendocrine cells of the gastric fundus. Plasma ghrelin rises sharply before meals and falls within 60 minutes of food ingestion, establishing it as a preprandial hunger signal. Additional ghrelin-producing cells are found in the small intestine, pancreas, hypothalamic arcuate nucleus, pituitary, and heart, though at far lower levels than the stomach.

Circulating half-life of acyl ghrelin is approximately 30 minutes in humans, limited by esterase-mediated deacylation and renal clearance. (PMID 38903769)

GHSR-1a: The Ghrelin Receptor

The growth hormone secretagogue receptor type 1a (GHSR-1a) is encoded by the GHSR gene (human chromosome 3q26.31, UniProt Q92847). It is a Class A (rhodopsin-family) GPCR with seven transmembrane helices, a short extracellular N-terminus, and three extracellular loops that together form the ligand-binding pocket.

Two splice variants are expressed from the GHSR locus:

• GHSR-1a (366 amino acids): the full-length, signaling-competent receptor. It constitutes the canonical ghrelin receptor.
• GHSR-1b (289 amino acids): a shorter form truncated after TM5, retained intracellularly and without intrinsic signaling capacity. GHSR-1b can heterodimerize with GHSR-1a and with other GPCRs, modulating their surface expression and pharmacology.

A defining property of GHSR-1a is constitutive (ligand-independent) activity: the receptor activates Gq/11 signaling at approximately 50% of maximal capacity even in the absence of ghrelin. (PMID 33747360, PMID 37687205) This unusually high basal activity is relevant to the pharmacology of inverse agonists versus neutral antagonists at this receptor. Mutations in the C-terminal intracellular tail, which mediates GPCR signal termination via beta-arrestin recruitment and receptor phosphorylation, can markedly enhance ghrelin responsiveness. In a rat model carrying the Q343X truncation mutation, loss of the C-terminal domain produces enhanced Gq-dependent signaling and blunted receptor desensitization, resulting in increased adiposity. (PMID 27095593)

GHSR-1a expression is highest in pituitary somatotrophs and hypothalamic arcuate and ventromedial nuclei; it is also expressed in hippocampus, substantia nigra, ventral tegmental area (VTA), dorsal raphe, brainstem vagal nuclei, cardiac myocytes, and peripheral metabolic tissues. (PMID 41643910)

Receptor Topology and Ligand-Binding Pocket

The orthosteric binding site occupies a deep transmembrane cavity formed primarily by TM3, TM4, TM5, TM6, and extracellular loop 2 (ECL2). The n-octanoyl chain of acyl ghrelin inserts into a hydrophobic sub-pocket, while the peptide backbone makes polar contacts with ECL2. The C-terminal glutamine of ghrelin contacts a different receptor region, contributing to binding affinity but not the initial trigger for receptor activation. Synthetic secretagogues such as ipamorelin and hexarelin occupy this same orthosteric pocket through distinct but overlapping contact networks. (PMID 16901923)

Upstream Context: Somatostatin Counterregulation

Before detailing downstream signals, somatostatin (SST) warrants mention as the principal inhibitory counter-signal at the somatotroph. Hypothalamic periventricular neurons secrete SST, which binds somatostatin receptors (SSTR1-5, predominantly SSTR2 and SSTR5 in somatotrophs) coupled to Gi. Gi-mediated suppression of adenylyl cyclase and opening of potassium channels oppose the excitatory signals of both ghrelin (via GHSR-1a/Gq) and GHRH (via GHRHR/Gs). Pulsatile GH secretion arises in part from the rhythmic alternation between hypothalamic GHRH and SST release. Synthetic GHSR-1a agonists exploit this architecture: by amplifying the peak-activating signal at the somatotroph, they enhance pulse amplitude without necessarily disrupting the underlying oscillator.

Downstream Signaling Cascades

Primary Effector: Gq/11-PLC-IP3-Ca2+ Cascade

Acyl ghrelin binding to GHSR-1a preferentially couples to the Gq/11 family of heterotrimeric G proteins. (PMID 16901923) The activated Galpha-q/11 subunit stimulates phospholipase C-beta (PLCbeta, PLCB1-4), which hydrolyzes the membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers:

1. Inositol 1,4,5-trisphosphate (IP3): diffuses to the endoplasmic reticulum membrane and binds IP3 receptors (IP3R, ITPR1/2/3), triggering Ca2+ release from intracellular stores.
2. Diacylglycerol (DAG): remains in the plasma membrane and activates protein kinase C (PKC, multiple PRKC isoforms).

Ca2+ release from stores initiates a biphasic signal: the initial transient from IP3-mediated ER release is followed by sustained Ca2+ influx through plasma membrane channels, including voltage-gated Ca2+ channels (VGCCs) opened by membrane depolarization secondary to PKC activity. In pituitary somatotrophs, this sustained Ca2+ elevation triggers exocytosis of GH-containing secretory granules. (PMID 16901923)

PKC-Mediated Downstream Events

DAG-activated PKC phosphorylates multiple substrates in somatotrophs and hypothalamic neurons:

• Voltage-gated Ca2+ channel subunits: enhancing Ca2+ influx and amplifying the secretory trigger.
• Components of the SNARE exocytotic machinery: facilitating vesicle docking and fusion.
• ERK1/2 (MAPK): PKC can activate the Ras-Raf-MEK-ERK cascade through PKC-dependent Ras-GRF activation, linking GHSR-1a signaling to transcriptional programs controlling somatotroph proliferation and GH gene expression.

Parallel Effector Arms

Beyond the primary Gq/11 arm, GHSR-1a activates several additional pathways:

(PMID 39057075)

Beta-Arrestin and Receptor Desensitization

Following sustained agonist activation, GHSR-1a is phosphorylated by G protein-coupled receptor kinases (GRKs), which creates docking sites for beta-arrestin 1/2 (ARRB1/2). Beta-arrestin binding sterically uncouples GHSR-1a from Gq, initiating desensitization and clathrin-mediated receptor internalization via endosomal compartments. Beta-arrestin also acts as a scaffold for the ERK1/2 cascade independently of G proteins, creating “biased” signaling where some effectors are activated after classical Gq signaling is silenced. The carboxyl-terminal tail of GHSR-1a is critical for this termination step: its truncation (as in the Q343X rat) substantially delays desensitization and prolongs downstream Ca2+ and MAPK signals. (PMID 27095593)

Signal Flow Diagram

flowchart TD
    subgraph Ligands["Upstream Ligands"]
        A["Acyl-ghrelin (GHRL, Q9UBS5)<br/>Ser3 n-octanoylated<br/>Stomach X/A-like cells"]
        B["GHRH (GHRH gene)<br/>Hypothalamic GHRH neurons"]
        C["Somatostatin (SST)<br/>Periventricular nucleus<br/>Inhibitory counter-signal"]
    end

    subgraph Receptors["Pituitary / CNS Receptors"]
        R1["GHSR-1a (Q92847)<br/>GHSR gene, Chr 3q26.31<br/>Constitutively active GPCR<br/>Gq/11 coupling"]
        R2["GHRHR (P32082)<br/>Hypothalamic/pituitary<br/>Gs coupling"]
        R3["SSTR2/5<br/>Gi coupling<br/>Inhibitory"]
    end

    subgraph GqArm["Gq/11 Arm (Primary)"]
        G1["Galpha-q/11 activation"]
        G2["PLCbeta activation"]
        G3["PIP2 hydrolysis"]
        G4["IP3 --> ER Ca2+ release"]
        G5["DAG --> PKC activation"]
        G6["Sustained Ca2+ influx (VGCC)"]
        G7["GH granule exocytosis"]
    end

    subgraph GsArm["Gs Arm (GHRHR parallel)"]
        S1["Galpha-s activation"]
        S2["Adenylyl cyclase"]
        S3["cAMP elevation"]
        S4["PKA activation"]
        S5["CREB Ser133 phosphorylation"]
        S6["GH1 gene transcription"]
    end

    subgraph DownstreamMisc["Additional Effectors"]
        D1["PI3K / Akt<br/>Anti-apoptotic; FOXO suppression"]
        D2["Ras-Raf-MEK-ERK1/2<br/>Somatotroph proliferation"]
        D3["Jak2 / STAT3<br/>Neuroprotection; neurogenesis"]
        D4["Beta-arrestin scaffold<br/>Internalization; biased ERK"]
    end

    subgraph Outputs["Physiological Outputs"]
        O1["Pulsatile GH release<br/>Somatotroph"]
        O2["IGF-1 synthesis<br/>Liver (GH-dependent)"]
        O3["Appetite / hunger signaling<br/>Hypothalamic ARC"]
        O4["Reward / mood<br/>VTA, hippocampus, SN"]
        O5["Energy metabolism<br/>Glucose, lipid homeostasis"]
    end

    subgraph Compounds["Research Compounds"]
        C1["Ipamorelin<br/>Selective GHSR-1a agonist"]
        C2["Hexarelin<br/>GHSR-1a agonist<br/>Pulsatile GH amplification"]
        C3["CJC-1295<br/>GHRH analog<br/>GHRHR / Gs arm"]
    end

    A -->|"Orthosteric binding"| R1
    B --> R2
    C -->|"Opposes GH release"| R3

    R1 --> G1
    G1 --> G2
    G2 --> G3
    G3 --> G4
    G3 --> G5
    G4 --> G6
    G5 --> G6
    G6 --> G7

    G5 --> D2
    R1 -->|"Gbetagamma / scaffold"| D1
    R1 -->|"Jak2 transactivation"| D3
    R1 -->|"GRK phosphorylation"| D4

    R2 --> S1
    S1 --> S2
    S2 --> S3
    S3 --> S4
    S4 --> S5
    S5 --> S6

    G7 --> O1
    S6 --> O1
    O1 --> O2
    R1 -->|"ARC neurons"| O3
    R1 -->|"VTA, hippocampus"| O4
    D1 --> O5
    D2 --> O5

    C1 -->|"GHSR-1a agonist"| R1
    C2 -->|"GHSR-1a agonist"| R1
    C3 -->|"GHRHR agonist"| R2

Physiological Outputs

Pulsatile Growth Hormone Secretion

Pituitary somatotrophs integrate excitatory signals from GHSR-1a (Gq) and GHRHR (Gs) with inhibitory signals from SSTR2/5 (Gi). The product of this integration is pulsatile GH release: discrete secretory bursts separated by troughs of near-zero GH, rather than continuous secretion. This pulsatility is physiologically critical because continuous GH exposure desensitizes the hepatic GH receptor (GHR, GHR, UniProt P10912), while pulsatile delivery maintains receptor responsiveness and drives robust downstream IGF-1 synthesis. (PMID 33368660)

GHSR-1a agonists increase GH pulse amplitude without systematically altering pulse frequency, consistent with their role in amplifying peak secretory events at the somatotroph rather than resetting the hypothalamic oscillator. Hexarelin research in obese mice demonstrated “significantly increased pulsatile GH secretion without detectable alteration on basal GH secretion,” accompanied by reduced visceral fat accumulation and improved insulin sensitivity. (PMID 33368660)

Pituitary-secreted GH enters the portal and systemic circulation, binds hepatic GHR, and drives IGF-1 synthesis in the liver. Circulating IGF-1 acts on virtually all tissues, promoting protein synthesis, cell proliferation, and substrate metabolism. The ghrelin/GHSR-1a axis is thus upstream of the entire GH-IGF-1 somatotrophic axis.

Appetite and Energy Balance

GHSR-1a expression on arcuate nucleus (ARC) AgRP/NPY neurons makes these cells direct ghrelin targets. Ghrelin binding activates the Gq/11-Ca2+ cascade and secondarily elevates cAMP in these neurons, stimulating the release of Agouti-Related Protein (AGRP) and Neuropeptide Y (NPY). AGRP acts as an inverse agonist at melanocortin MC3R and MC4R (see Melanocortin Axis), promoting food intake and suppressing energy expenditure. NPY acts on Y1/Y5 receptors in the paraventricular nucleus (PVN) to suppress satiety signaling.

Plasma acyl ghrelin rises in the preprandial state and during caloric restriction, functioning as a peripheral-to-central hunger signal. After meal ingestion, ghrelin falls within 60 minutes; this postprandial suppression is attenuated in obese individuals, contributing to impaired satiety signaling. (PMID 38903769)

GHSR-1a on POMC neurons exerts a counterbalancing role: ghrelin inhibits a subset of POMC neurons via Gq-driven activation of inhibitory interneurons, further amplifying the net orexigenic output of the ARC under fasting conditions.

Reward, Mood, and Neuroprotection

GHSR-1a expressed in the ventral tegmental area (VTA) and nucleus accumbens modulates dopaminergic transmission in the mesolimbic reward circuit. Ghrelin signaling in the VTA increases dopamine neuron firing, elevates dopamine release in the nucleus accumbens, and promotes food reward and hedonic eating. This circuitry also mediates ghrelin’s involvement in alcohol- and stress-related reward responses. (PMID 40442388)

In the hippocampus, GHSR-1a/Jak2/STAT3 signaling supports neurogenesis and synaptic plasticity. In the substantia nigra, GHSR-1a on dopaminergic neurons activates PI3K/Akt and reduces apoptosis, oxidative stress, and inflammatory cytokine production; preclinical evidence suggests neuroprotective roles in Parkinson’s disease models. (PMID 41643910)

GHSR-1a on hippocampal neurons also engages the cAMP/CREB/BDNF axis. BDNF (BDNF, UniProt P23560) upregulation downstream of CREB contributes to learning, memory consolidation, and antidepressant-like behavioral effects observed in ghrelin receptor activation studies. (PMID 39057075)

Peripheral Metabolic Effects

Beyond the pituitary and brain, GHSR-1a influences metabolism at several peripheral sites:

• Pancreatic islets: GHSR-1a on alpha cells stimulates glucagon secretion; on beta cells, it modulates insulin release in a glucose-dependent manner, contributing to the counter-regulatory response to hypoglycemia.
• Adipose tissue: ghrelin promotes lipid storage and attenuates adipocyte lipolysis under fasting conditions, conserving energy substrates.
• Cardiovascular: cardiac GHSR-1a activation promotes cardioprotective signaling through PI3K/Akt, reducing cardiomyocyte apoptosis; angiogenic effects via MAPK/ERK2 have also been described in endothelial cells. (PMID 22490634)
• Gastrointestinal tract: GHSR-1a in enteric neurons and smooth muscle promotes gastric motility and accelerates gastric emptying. This mechanism underlies ipamorelin’s studied activity in postoperative ileus models. (PMID 19289567)

Related Compounds

Ipamorelin

Ipamorelin (Ala-His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic pentapeptide-amide developed as a selective GHSR-1a agonist. Its defining characteristic relative to earlier growth hormone secretagogues (GHSs) is selectivity: ipamorelin produces GH release with minimal co-stimulation of ACTH, cortisol, prolactin, or LH at GH-releasing concentrations, a pharmacological profile attributed to receptor subtype selectivity and a more restricted downstream signal profile. Ipamorelin is described as “a selective growth hormone secretagogue and agonist of the ghrelin receptor” with dose-dependent GH release in preclinical studies. (PMID 19289567)

Beyond pituitary effects, ipamorelin’s activity at enteric GHSR-1a accelerates gastrointestinal motility and normalizes food intake in models of postoperative ileus. In a rodent model, repetitive ipamorelin dosing “significantly increased the cumulative fecal pellet output, food intake, and body weight gain” versus vehicle, with effects blocked by GHSR-1a antagonism, confirming on-target action. (PMID 19289567)

Research hub: Ipamorelin Research

Hexarelin

Hexarelin (His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2) is a six-amino-acid synthetic GHS that binds GHSR-1a and triggers the Gq/11-PLC-IP3-Ca2+ cascade described above. In pituitary cell models, “ghrelin signals through the Gq pathway” involving “Ca2+ release from intracellular stores followed by sustained elevation via influx of extracellular Ca2+ through ion channels”; hexarelin produced the same signaling pattern at comparable concentrations, confirming shared receptor engagement. (PMID 16901923)

In obese mouse models, hexarelin treatment “significantly increased the pulsatile GH secretion without detectable alteration on basal GH secretion.” Systemic effects included reduced visceral fat accumulation, lower liver triglyceride content, and improved insulin sensitivity, all consistent with restoring physiological GH pulsatility and its downstream GH-IGF-1 metabolic actions. (PMID 33368660)

Hexarelin also binds the scavenger receptor CD36 (CD36, UniProt P16671) at a site distinct from the ghrelin-binding orthosteric pocket of GHSR-1a, contributing to cardiac protection effects that persist even in GH-deficient animals, suggesting both GHSR-1a-dependent and GHSR-1a-independent mechanisms.

Research hub: Hexarelin Research

CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the 44-amino-acid hypothalamic peptide that acts on the GHRH receptor (GHRHR, GHRHR, UniProt P32082), a distinct GPCR from GHSR-1a. GHRHR couples to Gs, activating adenylyl cyclase, raising intracellular cAMP, and activating PKA in somatotrophs. This Gs/cAMP/PKA cascade phosphorylates CREB at Ser133 and drives transcription of the GH1 gene, increasing GH biosynthetic capacity in parallel with the secretory trigger provided by GHSR-1a agonists.

CJC-1295 incorporates the first 29 residues of GHRH (the pharmacophore) with several amino acid substitutions designed to improve proteolytic stability and, in the drug-affinity complex (DAC) version, a maleimide linker that allows covalent binding to circulating serum albumin, extending the effective half-life substantially relative to native GHRH (plasma t1/2 of minutes). (PMID 35298973)

Because CJC-1295 acts on GHRHR/Gs rather than GHSR-1a/Gq, it engages a mechanistically complementary but non-overlapping signaling arm. Co-administration of a GHSR-1a agonist (ipamorelin or hexarelin) with a GHRH analog (CJC-1295) produces supra-additive or synergistic GH release in preclinical models, reflecting the convergence of two distinct excitatory inputs onto the same somatotroph secretory apparatus.

Research hub: CJC-1295 Research

Key Molecular Targets Summary

Primary Literature

Pathway Context

The ghrelin/GHSR-1a axis feeds directly into the Growth Hormone Receptor signaling pathway (/pathways/growth-hormone-receptor/), since pulsatile GH is the primary product of GHSR-1a activation at the somatotroph. GH-driven hepatic IGF-1 synthesis is the domain of the IGF-1 signaling axis (/pathways/igf-1-signaling/), connecting this pathway to protein synthesis, cell proliferation, and tissue repair programs throughout the body. The ERK1/2 arm of GHSR-1a signaling joins the broader MAPK Cascade (/pathways/mapk-cascade/), through which ghrelin influences somatotroph differentiation and CNS neuronal survival. The PI3K/Akt arm intersects the PI3K-Akt Pathway (/pathways/pi3k-akt-pathway/), relevant to ghrelin’s anti-apoptotic and metabolic effects in peripheral tissues. Within the hypothalamic arcuate nucleus, the orexigenic output of GHSR-1a-activated AgRP neurons directly opposes the anorexigenic output of POMC neurons operating through the melanocortin system described in the Melanocortin Axis pathway page.

See also

Compounds that engage this pathway:

• Ipamorelin
• Hexarelin
• CJC-1295